Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03279601
Other study ID # CAPDTIC vs. CAPTEM
Secondary ID
Status Recruiting
Phase Phase 2
First received September 10, 2017
Last updated September 10, 2017
Start date September 1, 2017
Est. completion date September 1, 2020

Study information

Verified date September 2017
Source Peking University
Contact Lin Shen
Phone 86-10-88196561
Email linshenpku@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.In this prospective randomized phase II study, the investigators aim to compare the survival benefit as well as the safety forCapecitabine Combined With Dacarbazine(CAPDTIC) versus Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.


Recruitment information / eligibility

Status Recruiting
Enrollment 148
Est. completion date September 1, 2020
Est. primary completion date September 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. sign written informed consent form

2. age = 18 years

3. pathologically confirmed well-differentiated neuroendocrine tumor;

4. No prior antitumor treatment of capecitabine, dacarbazine or temozolomide. For recurrent patients after radical surgery, adjuvant chemotherapy should not include capecitabine, dacarbazine or temozolomide, and the last date should beyond 6 months prior to randomization;

5. At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions);

6. Screening laboratory values must meet the following criteria (within past 7 days): hemoglobin = 9.0 g/dL; neutrophils = 1500 cells/ µL; platelets = 100 x 10^3/ µL; total bilirubin = 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) = 2.5 x ULN without, and = 5 x ULN with hepatic metastasis; serum creatinine =1?ULN;

7. KPS = 70;

8. Predicted survival >=3 months;

9. Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women;

10. Sexually active males or females willing to practice contraception during the study until 30 days after end of study.

Exclusion Criteria:

1. Hypersensitivity to capecitabine, dacarbazine or temozolomide;

2. Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;

3. Received surgery within past 4 weeks, or have not recovered from surgery;

4. Severe diarrhea;

5. Concurrent severe infection;

6. Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including severe liver disease (active hepatitis, cirrhosis), uncontrolled diabetes or hypertension, or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);

7. Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to > 2 weeks of study enrollment);

8. Meningeal carcinomatosis;

9. Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease;

10. Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency;

11. Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study;

12. History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible;

13. Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons;

14. Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Capecitabine, Dacarbazine
Capecitabine: 1000mg/m2 ,p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ,iv drip,d1-5 q4W
Capecitabine, Temozolomide
Capecitabine: 1000mg/m2 ,p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ,p.o. bid d10-14 q4W,

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate (ORR) CT/MRI will be performed every 2 cycles of treatment by RECIST 1.1 From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary Progression-free survival Progression-free survival is defined as the time from the date of first dose to the date of the first documented radiological progression or death due to any cause baseline, every 8 weeks up to 1 year after last patient first treatment
Secondary Overall survival Overall survival is defined as the time from date of start of treatment to date of death due to any cause baseline, every 8 weeks up to 1 year after last patient first treatment
Secondary Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
See also
  Status Clinical Trial Phase
Completed NCT01218555 - Study of Everolimus (RAD001) in Combination With Lenalidomide Phase 1
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Withdrawn NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT02815969 - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Completed NCT02132468 - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Phase 2
Completed NCT02134639 - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation N/A
Recruiting NCT01201096 - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) N/A
Terminated NCT01163526 - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies N/A
Completed NCT01099228 - Combination Targeted Radiotherapy in Neuroendocrine Tumors N/A
Completed NCT00171873 - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Phase 3
Active, not recruiting NCT05077384 - Open-label Study of Surufatinib in Japanese Patients Phase 1/Phase 2
Active, not recruiting NCT04544098 - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Early Phase 1
Active, not recruiting NCT02736500 - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors Phase 1/Phase 2